1. Zanotti C, Martinez-Puente C, Pascual I, et al. (2007): An assessment of the incidence of fistula-in-ano in four countries of the European Union. Int J Colorectal Dis 22: 1459-1462.
2.
Sainio P (1984): Fistula-in-ano in a defined population. Incidence and epidemiological aspects. Ann Chir Gynaecol 73: 219-224.
3.
Mahadev S, Young JM, Selby W, Solomon MJ (2011): Quality of life in perianal Crohn’s disease: what do patients consider important? Dis Colon Rectum 54: 579-585.
4.
Cadeddu F, Salis F, Lisi G, et al. (2015): Complex anal fistula remains a challenge for colorectal surgeon. Int J Colorectal Dis 30: 595-603.
5.
Peyrin-Biroulet L, Bouhnik Y, Roblin X, et al. (2017): French national consensus clinical guidelines for the management of Crohn’s disease. Dig Liver Dis 49: 368-377.
6.
Lightner AL, Ashburn JH, Brar MS, et al. (2020): Fistulizing Crohn’s disease. Curr Probl Surg 57: 100808.
7.
Panés J, Reinisch W, Rupniewska E, et al. (2018): Burden and outcomes for complex perianal fistulas in Crohn’s disease: Systematic review. World J Gastroenterol 24: 4821-4834.
8.
Ardizzone S, Maconi G, Colombo E, et al. (2004): Perianal fistulae following infliximab treatment: clinical and endosonographic outcome. Inflamm Bowel Dis 10: 91-96.
9.
DelaRosa O, Dalemans W, Lombardo E (2012): Mesenchymal stem cells as therapeutic agents of inflammatory and autoimmune diseases. Curr Opin Biotechnol 23: 978-983.
10.
Garcia-Olmo D, Schwartz DA (2015): Cumulative evidence that mesenchymal stem cells promote healing of perianal fistulas of patients with Crohn’s disease – going from bench to bedside. Gastroenterology 149: 853-857.
11.
Jones BJ, McTaggart SJ (2008): Immunosuppression by mesenchymal stromal cells: from culture to clinic. Exp Hematol 36: 733-741.
12.
García-Olmo D, García-Arranz M, Herreros D, et al. (2005): A phase I clinical trial of the treatment of Crohn’s fistula by adipose mesenchymal stem cell transplantation. Dis Colon Rectum 48: 1416-1423.
13.
Herreros MD, Garcia-Arranz M, Guadalajara H, et al. (2012): Autologous expanded adipose-derived stem cells for the treatment of complex cryptoglandular perianal fistulas: a phase III randomized clinical trial (FATT 1: fistula Advanced Therapy Trial 1) and long-term evaluation. Dis Colon Rectum 55: 762-772.
14.
Garcia-Olmo D, Herreros D, Pascual I, et al. (2009): Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis Colon Rectum 52: 79-86.
15.
Molendijk I, Bonsing BA, Roelofs, H, et al. (2015): Allogeneic bone marrow-derived mesenchymal stromal cells promote healing of refractory perianal fistulas in patients with Crohn’s disease. Gastroenterology 149: 918-927.e6.
16.
Panés J, García-Olmo D, Van Assche G, et al. (2016): Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn’s disease: a phase 3 randomised, double-blind controlled trial. Lancet 388: 1281-1290.
17.
Zhou C, Li M, Zhang Y, et al. (2020): Autologous adipose-derived stem cells for the treatment of Crohn’s fistula-in-ano: an open-label, controlled trial. Stem Cell Res Ther 11: 124.
18.
Ascanelli S, Zamboni P, Campioni D, et al. (2021) Efficacy and Safety of treatment of complex idiopathic fistula-in-ano using autologous centrifuged adipose tissue containing progenitor cells: A randomized controlled trial. Dis Colon Rectum 64: 1276-1285.
19.
Garcia-Olmo D, Gilaberte I, Binek, M, et al. (2022): Follow-up study to evaluate the Long-term safety and efficacy of darvadstrocel (Mesenchymal Stem Cell Treatment) in patients with perianal fistulizing Crohn’s Disease: ADMIRE-CD Phase 3 Randomized Controlled Trial. Dis Colon Rectum 65: 713-720.
20.
Panés J, Bouma G, Ferrante M, et al. (2022): Inspect: A retrospective study to evaluate long-term effectiveness and safety of Darvadstrocel in patients with perianal fistulizing Crohn’s disease treated in the ADMIRE-CD trial. Inflamm Bowel Dis 28: 1737-1745.
21.
Panés J, García-Olmo D, Van Assche G, et al. (2018): Long-term efficacy and safety of stem cell therapy (Cx601) for complex perianal fistulas in patients with Crohn’s disease. Gastroenterology 154: 1334-42.e1334.
22.
Guadalajara H, Herreros D, De-La-Quintana P, et al. (2012): Long-term follow-up of patients undergoing adipose-derived adult stem cell administration to treat complex perianal fistulas. Int J Colorectal Dis 27: 595-600.
23.
Cheng F, Huang Z, Li Z (2020): Efficacy and safety of mesenchymal stem cells in treatment of complex perianal fistulas: A meta-analysis. Stem Cells Int 2020: 8816737.
24.
Choi S, Jeon BG, Chae G, Lee SJ (2019): The clinical efficacy of stem cell therapy for complex perianal fistulas: a meta- analysis. Tech Coloproctol 23: 411-427.
25.
Cao Y, Su Q, Zhang B, et al. (2021): Efficacy of stem cells therapy for Crohn’s fistula: a meta-analysis and systematic review. Stem Cell Res Ther 12: 32.
26.
Li A, Liu S, Li L, Yu M (2023): Mesenchymal stem cells versus placebo for perianal fistulizing Crohn’s disease: A systemic review and meta-analysis. Surg Innov 30: 398-405.
27.
Amil-Dias J, Kolacek S, Turner D, et al. (2017): Surgical management of Crohn disease in children: Guidelines from the paediatric IBD Porto Group of ESPGHAN. J Pediatr Gastroenterol Nutr 64: 818-835.
28.
Herman Y, Rinawi F, Rothschild B, et al. (2017): The characteristics and long-term outcomes of pediatric Crohn’s disease patients with perianal disease. Inflamm Bowel Dis 23: 1659-1665.
29.
Brückner A, Werkstetter KJ, de Laffolie J, et al. (2018): Incidence and risk factors for perianal disease in pediatric Crohn disease patients followed in CEDATA-GPGE registry. J Pediatr Gastroenterol Nutr 66: 73-78.
30.
Van Assche G, Dignass A, Reinisch W, et al. (2010): The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: Special situations. J Crohns Colitis 4: 63-01.
31.
Hinterleitner TA, Petritsch W, Aichbichler B, et al. (1997): Combination of cyclosporine, azathioprine and prednisolone for perianal fistulas in Crohn’s disease. Z Gastroenterol 35: 603-608.
32.
Lennard-Jones JE (1983): Toward optimal use of corticosteroids in ulcerative colitis and Crohn’s disease. Gut 24: 177-181.
33.
Sandborn WJ, Present DH, Isaacs KL, et al. (2003): Tacrolimus for the treatment of fistulas in patients with Crohn’s disease: a randomized, placebo-controlled trial. Gastroenterology 125: 380-388.
34.
Ryan JM, Barry F, Murphy JM, Mahon BP (2007): Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin Exp Immunol 149: 353-363.
35.
Horton JA, Hudak KE, Chung EJ, et al. (2013): Mesenchymal stem cells inhibit cutaneous radiation-induced fibrosis by suppressing chronic inflammation. Stem Cells 31: 2231-2241.
36.
Pezato R, de Almeida DC, Bezerra TF, et al. (2014): Immunoregulatory effects of bone marrow-derived mesenchymal stem cells in the nasal polyp microenvironment. Mediators Inflamm 2014: 583409.
37.
English K (2013): Mechanisms of mesenchymal stromal cell immunomodulation. Immunol Cell Biol 91: 19-26.
38.
Ivanova-Todorova E, Bochev I, Mourdjeva M, et al. (2009): Adipose tissue-derived mesenchymal stem cells are more potent suppressors of dendritic cells differentiation compared to bone marrow-derived mesenchymal stem cells. Immunol Lett 126: 37-42.
